TY - JOUR
T1 - Immunotherapy may protect cancer patients from SARS-CoV-2 infection
T2 - a single-center retrospective analysis
AU - Isgrò, Maria Antonietta
AU - Vitale, Maria Grazia
AU - Celentano, Egidio
AU - Nocerino, Flavia
AU - Porciello, Giuseppe
AU - Curvietto, Marcello
AU - Mallardo, Domenico
AU - Montagnese, Concetta
AU - Russo, Luigi
AU - Zanaletti, Nicoletta
AU - Avallone, Antonio
AU - Pensabene, Matilde
AU - De Laurentiis, Michelino
AU - Centonze, Sara
AU - Pignata, Sandro
AU - Cannella, Lucia
AU - Morabito, Alessandro
AU - Caponigro, Francesco
AU - Botti, Gerardo
AU - Masucci, Giuseppe Valentino
AU - Giannarelli, Diana
AU - Cavalcanti, Ernesta
AU - Ascierto, Paolo Antonio
N1 - Funding Information:
P.A.A. has/had a consultant/advisory role for Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Array, Merck Serono, Pierre-Fabre, Incyte, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo. He also received research funding from Bristol Myers Squibb, Roche-Genentech, Array and travel support from MSD. All the other authors declared to have no conflict of interest.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Coronavirus disease 2019 (COVID-19) global pandemic has created unique challenges to healthcare systems throughout the world. Ensuring subjects’ safety is mandatory especially in oncology, in consideration of cancer patients’ particular frailty. We examined the proportion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgM and/or IgG positive subjects in three different groups from Istituto Nazionale Tumori – IRCCS “Fondazione G. Pascale” in Naples (Campania region, Italy): cancer patients treated with Innovative Immunotherapy (Immune Checkpoint Inhibitors, ICIs), cancer patients undergoing standard Chemotherapies (CHTs) and healthcare providers. 9 out of 287 (3.1%) ICIs patients resulted positive, with a significant lower percentage in respect to CHTs patients (39 positive subjects out of 598, 6.5%) (p = 0.04). There was no statistically significant difference between ICIs cohort and healthcare providers, 48 out of 1050 resulting positive (4.6%). Performing a Propensity Score Matching based on gender and tumor stage, the effect of treatment on seropositivity was analyzed through a regression logistic model and the ICIs treatment resulted to be the only protective factor significantly (p = 0.03) associated with positivity (odds ratio—OR: 0.41; 95% confidence interval—CI 0.18–0.91). According to these preliminary data, ICIs would appear to be a protective factor against the onset of COVID-19 infection.
AB - Coronavirus disease 2019 (COVID-19) global pandemic has created unique challenges to healthcare systems throughout the world. Ensuring subjects’ safety is mandatory especially in oncology, in consideration of cancer patients’ particular frailty. We examined the proportion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgM and/or IgG positive subjects in three different groups from Istituto Nazionale Tumori – IRCCS “Fondazione G. Pascale” in Naples (Campania region, Italy): cancer patients treated with Innovative Immunotherapy (Immune Checkpoint Inhibitors, ICIs), cancer patients undergoing standard Chemotherapies (CHTs) and healthcare providers. 9 out of 287 (3.1%) ICIs patients resulted positive, with a significant lower percentage in respect to CHTs patients (39 positive subjects out of 598, 6.5%) (p = 0.04). There was no statistically significant difference between ICIs cohort and healthcare providers, 48 out of 1050 resulting positive (4.6%). Performing a Propensity Score Matching based on gender and tumor stage, the effect of treatment on seropositivity was analyzed through a regression logistic model and the ICIs treatment resulted to be the only protective factor significantly (p = 0.03) associated with positivity (odds ratio—OR: 0.41; 95% confidence interval—CI 0.18–0.91). According to these preliminary data, ICIs would appear to be a protective factor against the onset of COVID-19 infection.
KW - Chemotherapy
KW - ICIs
KW - Immunotherapy
KW - SARS-CoV-2 infections
KW - SARS-CoV-2 seropositivity
UR - http://www.scopus.com/inward/record.url?scp=85103743939&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103743939&partnerID=8YFLogxK
U2 - 10.1186/s12967-021-02798-2
DO - 10.1186/s12967-021-02798-2
M3 - Article
C2 - 33789686
AN - SCOPUS:85103743939
VL - 19
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
SN - 1479-5876
IS - 1
M1 - 132
ER -